Education
About Us
Working with TipRanks
Follow Us
Sujal Shah Insider Profile
4 Followers
Sujal Shah, CEO, Director at CymaBay Therapeutics, holds 0.00 shares in CymaBay Therapeutics (Ticker: CBAY), holds ― shares in Tvardi Therapeutics (Ticker: TVRD).
Profitable Transactions
6 out of 11 Profitable Transactions
Average Return
+35.10%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Sujal Shah does not currently own shares as a corporate insider.
A breakdown of Sujal Shah's holdings
Insider Roles
Director
Roles that Sujal Shah holds in companies
Most Profitable Insider Trade
Stock:
CymaBay Therapeutics
(CBAY)
(CBAY)
Rating:Informative Buy
Date:Jun 07, 2022 - Jun 07, 2023
Return:+306.00%
The most profitable trade made by Sujal Shah
Sujal Shah's Trading History
CymaBay Therapeutics
Mar 22, 2024
―
Uninformative Sell
―
$0.00
Tvardi Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Sujal Shah's performance on stock
You May Also Like
Sujal Shah insider profile FAQ
What is the percentage of profitable transactions made by Sujal Shah?
The percentage of profitable transactions made by Sujal Shah is 55%.
What is the average return per transaction made by Sujal Shah?
The average return per transaction made by Sujal Shah is 35.10%.
What stocks does Sujal Shah hold?
Sujal Shah holds: CBAY, TVRD stocks.
What was Sujal Shah’s latest transaction?
Sujal Shah latest transaction was an Uninformative Sell of ―.
What was Sujal Shah's most profitable transaction?
Sujal Shah’s most profitable transaction was an Informative Buy of CBAY stock on June 7, 2022. The return on the trade was 306.00%.
What is Sujal Shah's role in CymaBay Therapeutics?
Sujal Shah's role in CymaBay Therapeutics is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.